Abstract The goal of this study was to analyze results and to determine factors affecting outcome of HLA-matched hematopoetic stem cells transplantation (MRD-HSCT) for patients with acute leukemia transplanted in first complete remission in Eastern European countries. Six hundred forty HSCT were performed between 1990 and 2006 for adults with acute myeloid (n=459) and lymphoblastic (n=181) leukemia. Two-year leukemia-free survival (LFS), nonrelapse mortality (NRM), and relapse incidence were 58±2%, 19±2%, and 23±2%, respectively. The cumulative incidence of NRM decreased from 22±2% for patients treated between 1990 and 2002 to 15±3% for transplantations performed between 2003 and 2006 (p=0.02), despite increasing recipient age. In a multivariate analysis, time of HSCT affected both NRM and LFS. Among other prognostic factors, the use of TBI decreased relapse incidence and increased the LFS rate. We conclude that results of MRD-HSCT for acute leukemia in Eastern Europe improved over time as a consequence of decreased NRM. The use of TBI containing regimens appears advantagous.
Introduction
Allogeneic hematopoietic stem cell transplantation from HLA-matched related donor (MRD-HSCT) is a wellrecognized option for the treatment of patients with acute leukemia in first complete remission (CR). The benefit of MRD-HSCT over conventional-dose chemotherapy with regard to relapse rate has been demonstrated in a number of analyses for both acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) [1] [2] [3] [4] [5] [6] [7] [8] [9] . The number of MRD-HSCT for acute leukemia in Europe has been continuously growing over the last decades [10] . However, as demonstrated by Gratwohl et al., transplantation rates varied strongly between countries, which in major part could be explained by different economical conditions defined by the gross national income (GNI) per capita [11] . In particular, the number of MRD-HSCT procedures performed per year per ten million inhabitants between year 1990 and 2003 in Eastern European countries, representing medium GNI per capita, was markedly lower compared to Western Europe [12] . This difference resulted initially from later introduction of MRD-HSCT in Eastern countries but has been maintained over years as a consequence of parallel increase in transplantation rates in both parts of the continent [12] .
Among various factors influencing outcome of MRD-HSCT, the role of center effect has been highlighted in recent years. Frassoni at al. demonstrated that NRM varies strongly among transplant centers and that this phenomenon can partially be explained by the differences regarding team experience [13] . Provided that the MRD-HSCT has been widely introduced in Eastern Europe in the 1990s, i.e., approximately a decade later than in Western countries, it may be hypothesized that results in Eastern Europe are inferior and are characterized by higher rate of NRM. This issue is of particular importance in acute leukemia where the expected incidence of transplantation-related deaths should be taken into account for treatment decisions.
The goal of this study was to evaluate results of MRD-HSCT for acute leukemia patients in Eastern Europe and to determine if the outcome changed over time. In addition, we searched for other prognostic factors related to donor, recipient, and procedure characteristics.
Patients and methods

Study design and data collection
This was a retrospective multicenter analysis. Data were provided by the registry of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Centers participating in the EBMT are annually requested to report all consecutive stem cell transplantations and follow-up. The validation and quality control program includes verification of the computer print-out of the entered data, cross-checking with the national registries, and on-site visits of selected teams.
Criteria of selection
Inclusion criteria for the analysis were as follows: (1) Diagnosis of AML or ALL, (2) Age ≥16 years, (3) MRD-HSCT performed between 1990 and 2006 in Eastern European countries, including those that entered the European Union after 2003 and those not being memberstates of the European Union, and (4) CR1 at transplantation.
Patients, donors, and procedure Six hundred forty patients with the diagnosis of AML (n= 459) or ALL (n=181) were included in the analysis. Transplantations were performed in 32 centers representing 10 countries (Poland, n=178; Czech Republic, n=133; Croatia, n=60; Hungary, n=52; Slovakia, n=40; Slovenia, n=29; Serbia, n=17; Estonia, n=7; Romania, n=6; Lithuania, n=1). Median age of the recipients equaled 35 years (range, 16-69 years). Selection of donors was based either on serological or molecular methods at low resolution level.
All patients and donors were fully matched for HLA-A, HLA-B, and HLA-DR. The data on pre-transplant CMV serological status were available in 201 patient/donor pairs. CMV positivity was established in 63% of patients and 62% of donors. The conditioning regimen was myeloablative in 90% of cases and was based on either total body irradiation (TBI, mainly for ALL) or chemotherapy alone (predominantly for AML). Definition of reduced intensity conditioning regimen was considered lower dose of busulfan (less than 8 mg/kg total dose) or TBI (less than 6 Gy). The transplantations were performed using bone marrow (BMT) and peripheral blood (PBSCT) as a sources of stem cells in similar proportions. Ex vivo T-depletion was applied in seven cases (1%). After transplantation patients were monitored CMV antigenemia or CMV-DNA. Detailed characteristics of patients, donors, and MRD-HSCT procedure are listed in Table 1 
Statistical analysis
The following factors were analyzed for their prognostic value on each of the outcomes: year of MRD-HSCT, the diagnosis, interval from diagnosis to MRD-HSCT, recipient and donor characteristics (age, sex), and transplantation procedure (regimen intensity, use of TBI, stem cell source).
The probabilities of leukemia-free survival (LFS), relapse incidence (RI), and nonrelapse mortality (NRM) were the primary study endpoints. The LFS was defined as time interval from MRD-HSCT to either relapse or death in remission and was calculated using the Kaplan-Meier estimate. The RI and NRM were calculated using cumulative incidence curves in a competing risks setting, death in remission being treated as a competing event to relapse [14, 15] . Univariate analyses were done with the use of log-rank test for LFS while Grey's test was applied for RI and NRM. Continues variables were first categorized to divide the study group in five equal cohorts. Based on results of initial analysis, the final cutoff points were selected to be used in multivariate models. All potential prognostic factors with a p value less than 0.20 in univariate analyses were included in the Cox proportional hazard model, together with year of transplantation, diagnosis, and recipient age.
Additional study endpoints included engraftment and acute graft-versus-host disease (GVHD), which were reported as proportions, the probability of the overall survival (OS) estimated using the Kaplan-Meier method, and chronic graft-vs.-host, analyzed as cumulative incidence, relapse and death in remission being considered as competing. For the comparisons of transplant characteristics in various periods, Mann-Whitney U test and χ 2 test were used, as appropriate. All p values are two-sided with type 1 error rate fixed at 0.05. Statistical analyses were performed with SPSS (Inc., Chicago) and S-Plus (MathSoft, Inc, Seattle) software packages.
Results
Engraftment and GVHD
Six hundred thirteen out of 632 evaluable patients (97%) engrafted with the median time to neutrophil >0.5×10 9 /L recovery of 18 days (range, 5-60 days). The incidence of primary graft failure was 3% while secondary graft loss was diagnosed in 0.5% cases. One hundred fifty-seven out of 615 eligible patients (26%) experienced grade II-IV acute GVHD, whereas the 2-year probability of chronic GVHD was 29±2%.
Nonrelapse mortality
With the median follow-up of 21 months (range, 1-157 months), the cumulative incidence of NRM was 19 (standard error (SE) ±2%; Fig. 1 ). For MRD-HSCT performed between years 1990 and 2002, the rates of NRM did not change significantly while the outcome for transplantations performed after 2002 improved in comparison with the preceding period (22±2% vs. 15±3%, p= 0.02; Fig. 2) . In a multivariate analysis, the only factors affecting the risk of NRM were the year of transplantation (HR=0.58 for MRD-HSCT performed after year 2002) and the recipient age ≥40 years (HR=1.48; Table 2 ).
Relapse incidence
The cumulative incidence of RI was 23±2% for all patients (Fig. 1) , 22±3% for AML, and 25±3% for ALL. No changes of RI rates were observed over time. In both univariate and multivariate analysis the use of peripheral blood resulted in increased risk of RI (HR=1.63) whereas female donor gender (HR=0.63), interval from diagnosis to MRD-HSCT≥9 months (HR=0.44), and TBI-based conditioning (HR=0.52) were associated with reduced incidence of relapse (Table 2) .
Survival
The 2-year probabilities of OS and LFS for the whole group equaled 65±2% and 58±2%, respectively (Fig. 1) . The LFS rates were 59±3% for AML patients, and 55±4% for ALL. Although the probabilities of LFS did not change markedly over time, in a multivariate model adjusted for other potential prognostic factors, the risk of failure for transplantations performed after 2002 was significantly reduced in comparison with the preceding period (HR= 0.71; Table 2 ). As shown in Table 3 , patients treated with MRD-HSCT between 2003 and 2006 were characterized by higher age, shorter interval from diagnosis to transplantation as well as more frequent use of PBSCT and reduced intensity regimens, compared to years 1990-2002.
In the whole study group, independently from the year of transplantation, the probability of LFS was adversely affected by the recipient age ≥40 years (HR=1.33), the diagnosis of ALL (HR=1.32) and the use of peripheral blood as a source of stem cells (HR=1.33), while the use of TBI (HR=0.64) and longer interval from diagnosis to transplantation (HR=0.69) were associated with better outcome ( Table 2) .
The univariate analysis revealed that the probability of LFS was significantly lower for patients treated with reduced-intensity regimens (RIC) compared to myeloablative conditioning (MAC; 44±8% vs. 59±2%, p=0.02), which resulted from increased RI (37±2% vs. 22±8%, p= 0.02). As all RIC transplantations were performed with the use of peripheral blood stem cells, the conditioning intensity and stem cell source could not be included together in the Cox model. However, in a subgroup analysis restricted to PBSCT, no significant difference could be demonstrated for RIC compared to MAC. Therefore, in contrast to stem cells source, the regimen intensity has not been considered for multivariate analyzes.
The effect of stem cell source was further analyzed in subgroups defined by the diagnosis as well as with restriction to MAC transplantations only. For AML patients receiving myeloablative conditioning the probability of LFS was higher after BMT compared to PBSCT (66±3% vs. 54±5%, p=0.025), which was mainly a consequence of reduced RI (16±3% vs. 27±4%, p=0.01). In contrast, in a cohort of ALL, no significant influence on outcome could be demonstrated for the stem cell source. The comparison of patients receiving BMT and PBSCT revealed that the use of peripheral blood was associated with significantly increased recipient age Before 2003, LFS was 45±5% for patients receiving PBSCT compared to 63±3% for those receiving BMT (p=0.002), while in the later period, LFS was 59±5% and 63±8%, respectively (p=0.52).
The effect of conditioning regimen on outcome was observed for both AML and ALL subgroups. In AML patients, the use of TBI-based conditioning resulted in decreased incidence of NRM as compared to chemotherapy alone (11±4% vs. 20±2%, p=0.04), which translated into higher LFS (70±6% vs. 57±3%, p=0.01). ALL patients treated with TBI experienced significantly less relapses as compared to chemotherapy-based regimens (18±4% vs. 34±6%, p=0.009), although the impact of conditioning on LFS was not significant. Despite these features, which in multivariate models were found to adversely affect outcome, the 2-year probability of LFS increased and reached the level of 60%. The major improvement was observed in terms of the NRM, which in recent years decreased to 15%. Reasons of this phenomenon may only be a subject of speculation, but probably better control of infections and GVHD should be considered. On the other hand, it may be speculated that in recent years, transplant centers preferred to use conditioning regimens with partially reduced intensity not fulfilling, however, the arbitrary criteria of RIC. Unfortunately, in this registry-based analysis, we were unable to evaluate this factor in the multivariate models due to insufficient data. Our findings regarding NRM are of particular importance as high mortality rates have been raised a major counterargument to use MRD-HSCT in frontline therapy of adults with acute leukemia, especially in ALL. In a recently published study on a large population of patients, Goldstone at al. failed to demonstrate advantage of MRD-HSCT over conventional-dose chemotherapy in a setting of high-risk ALL; however, the 2 years NRM rate for patients having an HLA-identical sibling was as high as 36% [3] . In the largest so far retrospective analysis including 2234 AML and ALL patients treated with MRD-HSCT in CR1 between 1994 and 2000, the NRM rate equaled 23% [16] . With all the limitations regarding potential selection bias, the results obtained in Eastern Europe seem encouraging. As analyses similar to our one have not been published in recent years, it may only be speculated that our findings reflect a global trend for reduction of NRM in acute leukemia patients. From the reasons given before, confirmation of such a trend seems essential to facilitate treatment decisions in this group of patients.
The univariate and multivariate analysis of prognostic factors revealed several unexpected findings. In particular, the effects of stem cell source and type of conditioning appear intriguing. Comparison of bone marrow and peripheral blood MRD-HSCT was a subject of several randomized studies, all including heterogeneous populations with regard to both the diagnosis and the disease status at transplantation [17] [18] [19] [20] [21] [22] . Recently updated results of the IBMTR/EBMT study revealed that for CR1 acute leukemia patients both sources of stem cells are equivalent with regard to all LFS, RI, and NRM [23] . In a metaanalysis performed for nine randomized trials, no difference was found for early stage leukemia, while patients with advanced AML benefited from the use of PBSCT [24] . On the other hand, in a retrospective study, based on the EBMT registry, Ringden at al. demonstrated higher RI for ALL CR1 patients receiving PBSCT compared to BMT, whereas no differences were found for AML [16] . In our study, the use PBSCT adversely affected LFS as a consequence of increased RI, which however, was observed only before 2003 and not in more recent period. Reliable interpretation of our results would require more detailed information on disease-related risk factors, particularly cytogenetic and molecular features that were unavailable in the current analysis.
TBI-based conditioning is widely accepted for ALL patients undergoing MRD-HSCT although until now, there is no direct evidence for its advantage over chemotherapy-based regimens [25] . In case of AML, the issue is even more controversial as some studies demonstrated better LFS after TBI compared to busulfan in combination with cyclophosphamide, while in other ones, such effect could not be confirmed [26] [27] [28] . A long-term follow-up of four randomized trials revealed a tendency for increased LFS and OS after TBI-based compared to busulfan-based conditioning [29] . In our analysis, the use of TBI was associated with improved LFS. In a cohort of ALL, TBI-based conditioning resulted in decreased risk of relapse, while in AML, with reduced NRM. These findings seem to support the use of TBI in acute leukemia patients, which, however, should be interpreted with caution taking into account the retrospective nature of our study.
We conclude that results of MRD-HSCT for acute leukemia in Eastern Europe improved over time, as a consequence of decreased NRM, despite increasing recipient age. Our results should enhance extended use of this procedure to be offered to a larger number of acute leukemia patients. This is of particular importance in countries were the transplant program is still in the early phase of development, as a consequence of insufficient financial support or unfavorable regulations. Further analyses are required to determine association of MRD-HSCT outcome with country-and center-specific socioeconomical factors.
